A new study by IIT researchers has shown that dextran/eudragit S-100 based redox sensitive nanoparticles (DEEU NPs) may be a promising tool for targeted therapy against colorectal cancer.
Bullet Point Summary:
- DEEU NPs were synthesized using a combination of natural and synthetic polymers
- The system was colloidally stable and released the drug in response to glutathione
- In vitro and in vivo studies showed that DEEU NPs were non-toxic and targeted colorectal cancer cells more efficiently than normal cells
- The NPs were localized to the liver, kidneys, and spleen after 1 hour, and complete colon localization was speculated after 24 hours
Researchers at the Indian Institute of Technology Mandi have synthesized dextran/eudragit S-100 based redox sensitive nanoparticles (DEEU NPs) as a potential tool for targeted therapy against colorectal cancer. The NPs were synthesized by reacting thiolated dextran with eucaratus under an air atmosphere and were found to be colloidally stable in a physiological environment. In vitro studies showed that the NPs were non-toxic to HCT116 colon cancer cells and were more efficient at killing cancer cells than free doxorubicin (DOX).
The in vitro and in vivo biodistribution of the NPs were investigated using non-invasive near-infrared fluorescence imaging, and it was observed that the NPs localized to the liver, kidneys, and spleen after 1 hour. The authors speculate that complete colon localization could be achieved after further time increments in the endpoint for ex vivo distribution.
Overall, the results of the study show that DEEU NPs have the potential to be a promising tool for targeted therapy against colorectal cancer, and further studies are needed to fully understand the efficacy and safety of these nanoparticles.
Dextran/eudragit S-100 based redox sensitive nanoparticles for colorectal cancer therapy
Li; Nanoscale; Gupta; Dhiman; Sood; Bharadwaj; Silverman; Agrawal
Full text link: https://doi.org/10.1039/d3nr00248a
What this paper is about
- A combination of both natural and synthetic polymers offers the opportunity of developing the nanoparticle matrix in such a way that it can perform the desired action in a complex biological environment.
- Dr Garima Agrawal is currently an assistant professor in the School of Chemical Sciences at the Indian Institute of Technology Mandi.
- Her research interests are in the fields of functional polymers, nanomaterials, and biomaterials.
What you can learn
- It was observed that 1 h after administration the DEEU NPs were localized to the liver, kidneys, and spleen.
- In addition, as signals in the stomach region decreased at 24 h after administration, it is speculated that further time increments in the endpoint for ex vivo distribution could result in complete colon localization of the designed DEEU NPs.
- The reported DEEU NPs were nontoxic up to 100 g mL 1 while DOX-DEEU NPs had higher efficiency for killing HCT116 colon cancer cells as compared to free DOX.
Q: What are DEEU NPs?
A: DEEU NPs are Dextran/eudragit S-100 nanoparticles synthesized by reacting thiolated dextran with eucaratus under an air atmosphere.
Q: How were the DEEU NPs synthesized?
A: The DEEU NPs were synthesized by reacting thiolated dextran with eucaratus under an air atmosphere.
Q: What is the purpose of the DEEU NPs?
A: The DEEU NPs were developed for colorectal cancer therapy as a redox sensitive nanoparticle system.
Q: How was the biodistribution of the DEEU NPs studied?
A: The in vitro and in vivo biodistribution of the DEEU NPs was investigated using a non-invasive NIR fluorescence imaging technique.
Q: What was the result of the in vitro toxicity study of DEEU NPs?
A: The in vitro toxicity study showed that the DEEU NPs were nontoxic with over 90% cell viability at all doses in the concentration range of 1100 g/mL, confirming their biocompatibility and biodegradability.
Q: What was the outcome of the DEEU NPs targeting efficiency evaluation?
A: The targeting efficiency of the DEEU NPs was evaluated using CLSM and it was found to be more efficient toward colorectal cancer cells than normal cells.
Q: What is Dr. Garima Agrawal’s field of study?
A: Dr. Garima Agrawal is an assistant professor in the School of Chemical Sciences at the Indian Institute of Technology Mandi and her research interests are in the fields of functional polymers, nanomaterials, and biomaterials.
Q: Where did the DEEU NPs localize 1 hour after administration?
A: The DEEU NPs localized in the liver, kidneys, and spleen 1 hour after administration.
Q: What is the result of the toxicity study of DOX-DEEU NPs compared to free DOX?
A: The DOX-DEEU NPs were found to have higher efficiency for killing HCT116 colon cancer cells compared to free DOX and were nontoxic up to 100 g/mL.
